Loading
A phase 1/2 trial of Vepdegestrant in advanced solid tumours, run by Pfizer, active and no longer recruiting.
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) is a phase 1/2 interventional study registered as NCT06125522 by Pfizer, with 11 participants enrolled, started 2024-01-10 and due to reach its primary completion in 2026-12-31. Interventions recorded: vepdegestrant and Samuraciclib.
Shares Vepdegestrant, PROTACs & molecular glues (targeted protein degradation), Endocrine therapy (SERMs, AIs, SERDs), Pfizer (incl. Seagen) and the tag pipeline.
Shares Vepdegestrant, PROTACs & molecular glues (targeted protein degradation), Endocrine therapy (SERMs, AIs, SERDs), Pfizer (incl. Seagen) and the tag pipeline.
Shares Vepdegestrant, PROTACs & molecular glues (targeted protein degradation), Endocrine therapy (SERMs, AIs, SERDs), Pfizer (incl. Seagen) and the tag pipeline.
Shares Vepdegestrant, PROTACs & molecular glues (targeted protein degradation), Endocrine therapy (SERMs, AIs, SERDs), Pfizer (incl. Seagen) and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pfizer (incl. Seagen), Metastatic cancer (cancer that has spread) and the tag pipeline.